Oncology Publications
This section includes links to select Pharmacosmos-sponsored* abstracts, posters, and publications, which cover pivotal trials and/or have appeared in peer reviewed journals and congress presentations.
Information about product(s), or investigational uses of product(s), does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Pharmacosmos does not recommend or suggest use of its product(s) in a manner inconsistent with FDA-approved labeling.
*G1 Therapeutics is now a subsidiary of Pharmacosmos Therapeutics Inc.
Clinical Trials
Phase 2 clinical trials performed in patients with extensive-stage small lung cancer that supported the FDA approval of trilaciclib. Additional analyses were performed with these data.
Real World Evidence
Retrospective real-world studies to understand clinical and economic burden of chemotherapy-induced myelosuppression in patients with extensive-stage lung cancer.
Preclinical Evidence and Clinical Pharmacology
Preclinical studies and clinical pharmacologic evaluations to understand the pathophysiologic mechanisms, therapeutic targets, and pharmacologic profile of an IV CDK4/6 inhibitor for chemotherapy-induced myelosuppression in extensive-stage lung cancer, including assessments of mechanism of action, pharmacokinetics, and pharmacodynamics.
Disease State Burden
Studies to characterize the clinical presentation, progression, and overall burden of chemotherapy-induced myelosuppression in patients with lung cancer, including its impact on patient outcomes and healthcare resource utilization.